RGBP (Regen BioPharma) Tariff Resilience Score: 4/10 (As of Jun. 27, 2026)


What is Regen BioPharma Tariff Resilience Score?

Regen BioPharma RGBP +33.33% Tariff Resilience Score is 4 as of Jun. 27, 2026. The stock has 7 warning signs investors should review. Among 1,378 Biotechnology companies, Regen BioPharma ranks better than 52.39% on this metric.

Regen BioPharma has the Tariff Resilience Score of 4, which implies that the company might have Average Resilient.

Regen BioPharma has Biotech industry can be vulnerable to tariffs on imported research materials. Global supply chain dependencies and limited pricing power increase risk.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Regen BioPharma might have Average Resilient.

Regen BioPharma  (OTCPK:RGBP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Regen BioPharma Tariff Resilience Score Related Terms

RGBP vs ENDV, ADTX, SCPX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Regen BioPharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regen BioPharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 4 mean?
Regen BioPharma (RGBP) has a Tariff Resilience Score of 4 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Regen BioPharma ranks #656 out of 1378 companies in the Biotechnology industry, placing it in the top 47.6%.
Is Regen BioPharma's Tariff Resilience Score too high?
Regen BioPharma's current Tariff Resilience Score is 4. The Biotechnology industry median Tariff Resilience Score is 4.00. Regen BioPharma's value of 4 is 0% at this industry median. Based on the distribution chart, Regen BioPharma ranks #656 out of 1378 companies in the Biotechnology industry, which is above the industry midpoint.
How does Regen BioPharma's Tariff Resilience Score compare to ENDV and ADTX?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #656 out of 1378 companies for Tariff Resilience Score. This puts Regen BioPharma in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Regen BioPharma's value of 4 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regen BioPharma's current Tariff Resilience Score of 4 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Tariff Resilience Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99% below its estimated fair value. The current Tariff Resilience Score is 4 and 0% at the Biotechnology industry median of 4.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Tariff Resilience Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regen BioPharma Business Description

Other Exchanges RGBPP.PFD:USA
Address 8697 La Mesa Boulevard, Suite C, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.